A Different Kind of Drug
CAR-T cell therapies are not small molecules. They are not even biologics in the conventional sense. They are living, replicating therapeutic agents: a patient’s own T cells, extracted, genetically modified to express a chimeric antigen receptor, expanded ex vivo, and reinfused to hunt and destroy tumour cells.
That extraordinary mechanism of action creates an equally extraordinary monitoring challenge. You cannot measure a CAR-T therapy with a plasma concentration assay. The drug proliferates, differentiates, and persists for months or years after a single dose. Monitoring it requires an entirely different bioanalytical toolkit.
What You Are Actually Measuring
CAR-T Cell Persistence
The key pharmacokinetic question for a CAR-T product is not concentration but persistence: are the CAR-T cells still present, and in what numbers? Quantitative PCR targeting the transgene sequence is the standard method for measuring CAR-T cell levels in peripheral blood over time. Flow cytometry using CAR-specific antibodies or antigen-binding probes provides complementary phenotypic data on the composition and activation state of the persisting cells.
Cytokine Release Monitoring
CAR-T therapies can trigger cytokine release syndrome (CRS), a potentially life-threatening inflammatory response caused by the rapid activation of T cells and bystander immune cells. Monitoring key cytokines including IL-6, IFN-gamma, and ferritin in plasma allows clinical teams to detect CRS early and intervene before it progresses to severe grades. The bioanalytical assay must be sensitive enough to detect early cytokine rises against a variable baseline.
Neurotoxicity Markers
Immune effector cell-associated neurotoxicity syndrome (ICANS) is the other major safety concern in CAR-T therapy. CSF biomarkers including GFAP and neurofilament light chain are being evaluated as early indicators of neurological inflammation. Reliable quantification of these markers in CSF, a matrix with very different properties from plasma, requires assay-specific validation.
The Bioanalytical Package for a CAR-T IND
| Assay | Matrix | Method | Regulatory Purpose |
| CAR-T cell quantification | Peripheral blood | ddPCR or qPCR targeting transgene; flow cytometry | PK characterisation; persistence data for safety assessment |
| Cytokine panel (IL-6, IFN-gamma, TNF-alpha, IL-2) | Plasma/serum | Multiplex MSD or single-plex ELISA | CRS monitoring; pharmacodynamic response |
| Anti-CAR antibody (ACA) detection | Serum | Bridging LBA; tiered immunogenicity strategy | Immunogenicity assessment; impact on cell persistence |
| CAR-T phenotyping (CD4/CD8, memory, exhaustion) | Peripheral blood | Multi-parametric flow cytometry | Pharmacodynamic characterisation; mechanism of action evidence |
| Tumour burden assessment | Blood (liquid biopsy) or tissue | ctDNA by NGS; tumour marker by validated immunoassay | Efficacy endpoint; correlation with CAR-T expansion |
| Safety biomarkers (GFAP, NfL for ICANS) | CSF / plasma | Digital ELISA (Simoa) or MSD | Neurotoxicity monitoring; exploratory safety biomarker |
The Validation Challenge: No Stable Reference Standard
One of the most practically difficult aspects of CAR-T bioanalysis is that the analyte itself, the genetically modified T cell, is not a stable reference standard. Cell-based assays cannot be validated in the same way as small molecule or protein assays. The cell population changes phenotype over time in culture, and the reference material used for one validation run may not be biologically equivalent to the material used for the next.
Regulatory guidance from both the FDA and the EMA has evolved to acknowledge this challenge. A fit-for-purpose approach is accepted for many CAR-T bioanalytical assays, where the validation scope is defined by the intended use of the data and the decisions it will support, rather than by the full panel of ICH M10 parameters applicable to a conventional drug concentration assay.
Ardena’s Cell Therapy Bioanalysis at Assen
Ardena’s bioanalytical team at Assen supports cell therapy programmes with ddPCR-based transgene quantification, multi-parametric flow cytometry for CAR-T phenotyping, multiplex cytokine assays, and immunogenicity testing for anti-CAR antibodies. The team takes a programme-specific approach to assay development and validation, working with sponsors to define the right level of validation rigour for each assay based on its role in the clinical decision-making framework.
